Welcome to our dedicated page for Tenax Therapeutics SEC filings (Ticker: TENX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Tenax Therapeutics, Inc. (TENX) provides access to the company’s official disclosures as a Nasdaq-listed, Phase 3, development-stage pharmaceutical company. Through these filings, Tenax reports material events, clinical and corporate milestones, and periodic financial results related to its cardiopulmonary drug development programs.
Recent Form 8-K filings have documented key developments in the company’s PH-HFpEF program. These include announcements that the European Patent Office issued an Intention to Grant a patent covering TNX‑103 (oral levosimendan), other levosimendan formulations, and its active metabolites for use in PH-HFpEF, and that Tenax completed a prespecified blinded sample size re-estimation in the registrational Phase 3 LEVEL trial of TNX‑103 in the United States and Canada. Other 8‑K filings describe the initiation of the global Phase 3 LEVEL‑2 study and amendments to the company’s license agreement with Orion Corporation, expanding Tenax’s rights to develop, commercialize, and manufacture orally administered levosimendan products.
Filings also include earnings-related 8-Ks, where Tenax furnishes press releases detailing quarterly financial results and corporate updates. These disclosures discuss research and development spending on the LEVEL and LEVEL‑2 trials, general and administrative expenses, and the company’s cash position and funding outlook, all within the framework of SEC reporting requirements.
On this page, users can review Tenax’s SEC submissions, including current reports and other documents that may be filed over time. Stock Titan enhances this information with AI-powered summaries that explain the significance of complex filings, highlight clinical and IP milestones, and help readers quickly identify items related to Phase 3 trial progress, licensing arrangements, and the company’s PH-HFpEF strategy. This resource supports investors and researchers seeking a structured view of TENX’s regulatory and financial reporting history.
Tenax Therapeutics received a Schedule 13G disclosing that affiliated investment vehicles controlled by Raymond Debbane hold meaningful common stock positions. Invus Public Equities directly holds 366,143 shares, reported as 8.0% of the class, and Avicenna Life Sci Master Fund directly holds 60,998 shares, reported as 1.3%. Collectively, Mr. Debbane is reported as the beneficial owner of 427,141 shares, or 9.4%, based on an outstanding share count of 4,562,500 as reported by the issuer. The filing states these positions are not held to change or influence control of the company.
Venrock-related entities and two individuals filed an amendment to Schedule 13G reporting collective beneficial ownership of 449,492 shares of Tenax Therapeutics common stock, representing 9.99% of the class as of June 30, 2025. The reported position includes a mix of common shares, pre-funded warrants and common warrants, but the warrants contain a Beneficial Ownership Blocker that prevents exercise that would raise ownership above 9.99%. Ownership is held through VHCP III, VHCP Co-Investment III and VHCP EG, with VHCP Management entities and Messrs. Shah and Koh serving managerial/voting roles.
Janus Henderson Group plc filed a Schedule 13G reporting that it may be deemed the beneficial owner of 166,666 shares of Tenax Therapeutics common stock, representing 4.0% of the class as reported. The filing states the filer has no sole voting or dispositive power and reports shared voting and shared dispositive power for 166,666 shares, indicating the position is held through collective or affiliated advisory vehicles rather than by an individual account.
The filing contains a certification that the securities were acquired and are held in the ordinary course of business and not to influence control. Item 7 identifies indirect subsidiaries (JHIUS, JHIUKL and JHIAIFML) as registered investment advisers furnishing advice to managed portfolios in connection with these holdings.
Tenax Therapeutics (TENX) reported interim results showing operational progress in its Phase 3 levosimendan program while funding its near-term development plan. The company held $105.5 million in cash and cash equivalents at June 30, 2025 and reported a six-month net loss of $21.3 million, contributing to an accumulated deficit of $336.1 million. Management believes existing resources are sufficient for at least the next 12 months and states they can continue operations through 2027.
The company increased R&D and G&A spending as it expanded the ongoing Phase 3 LEVEL study and prepared a second global Phase 3 trial, LEVEL-2, with planned enrollment of 230 patients expected to complete in the first half of 2026. Tenax completed a March 2025 private placement that generated gross proceeds of ~$25.0 million (net $23.2 million) and previously raised net proceeds of ~$92.3 million in August 2024 to support clinical programs. The company also has material outstanding warrants and pre-funded warrants and significant stock-based compensation expense recognized in the period.
Tenax Therapeutics has furnished a press release disclosing its financial results for the quarter ended June 30, 2025, attaching that release as Exhibit 99.1 to this Form 8-K. The company also included an interactive XBRL cover page as Exhibit 104 and reconfirmed that the press release is furnished rather than filed, so it is not subject to Section 18 liability and is not incorporated by reference into other filings except by specific reference. The 8-K itself does not include any numerical financial figures; readers must consult the attached press release for detailed results and metrics.
Tenax Therapeutics, Inc. (TENX) – Form 4 filing: Director Dr. June Sherie Almenoff reported the receipt of 80,000 stock options on 07/01/2025 at an exercise price of $5.75 per share. The options become exercisable on 07/01/2026 and expire on 07/01/2035. No common-stock transactions were reported. Following the grant, Dr. Almenoff now directly holds 80,000 newly issued options in addition to previously reported grants of 100,008 options (small lots dated 2022, 2023, and 2025). The filing reflects a routine equity incentive award to a non-employee director; it does not disclose any purchases or sales of TENX common shares.
Tenax Therapeutics (TENX) filed a Form 4 disclosing insider activity by director Michael H. Davidson on 1 July 2025.
- Equity grant: Davidson acquired 80,000 stock options with an exercise price of $5.75. The options become exercisable on 01-Jul-2026 and expire on 01-Jul-2035. No cash was paid at grant (price $0.00).
- Existing derivative holdings: The filing shows additional option positions of 100,000 options at $5.94, two small option lots (4 each) at $3,200 and $992, a 47,500 pre-funded warrant (strike $0.01, no expiration) and a 25,000 warrant (strike $4.50) that will lapse upon the earlier of several milestone events or 08-Aug-2029.
- Common shares: Davidson owns 2,881 shares directly after the reported transaction.
- Total derivative exposure: The table indicates 252,508 derivative securities (options + warrants) now beneficially owned.
No sales or dispositions of Tenax common stock were reported. The transactions appear to be part of routine director compensation and warrant structures related to prior financing rounds.
FAQ
What is the current stock price of Tenax Therapeutics (TENX)?
What is the market cap of Tenax Therapeutics (TENX)?
